MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors

Overview

Journal Sci Rep

Specialty Science

Date 2016 May 25

PMID 27217294

Citations 23

Authors

Masayuki Hiraki

Yozo Suzuki

Maroof Alam

Kunihiko Hinohara

Masanori Hasegawa

Caining Jin

Surender Kharbanda

Donald Kufe

Affiliations

Soon will be listed here.

Abstract

Aberrant expression of myeloid cell leukemia-1 (MCL-1) is a major cause of drug resistance in triple-negative breast cancer (TNBC) cells. Mucin 1 (MUC1) is a heterodimeric oncoprotein that is aberrantly overexpressed in most TNBC. The present studies show that targeting the oncogenic MUC1 C-terminal subunit (MUC1-C) in TNBC cells with silencing or pharmacologic inhibition with GO-203 is associated with downregulation of MCL-1 levels. Targeting MUC1-C suppresses the MEK → ERK and PI3K → AKT pathways, and in turn destabilizes MCL-1. The small molecules ABT-737 and ABT-263 target BCL-2, BCL-XL and BCL-w, but not MCL-1. We show that treatment with ABT-737 increases reactive oxygen species and thereby MUC1-C expression. In this way, MUC1-C is upregulated in TNBC cells resistant to ABT-737 or ABT-263. We also demonstrate that MUC1-C is necessary for the resistance-associated increases in MCL-1 levels. Significantly, combining GO-203 with ABT-737 is synergistic in inhibiting survival of parental and drug resistant TNBC cells. These findings indicate that targeting MUC1-C is a potential strategy for reversing MCL-1-mediated resistance in TNBC.

Citing Articles

Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.

Serrano Garcia L, Javega B, Llombart Cussac A, Gion M, Perez-Garcia J, Cortes J Front Immunol. 2024; 15:1513421.

PMID: 39735530 PMC: 11671371. DOI: 10.3389/fimmu.2024.1513421.

Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer.

Li L, Cao J, Chen C, Qin Y, He L, Gu H Heliyon. 2023; 9(4):e15164.

PMID: 37089317 PMC: 10113850. DOI: 10.1016/j.heliyon.2023.e15164.

Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer.

Spinola-Lasso E, Carlos Montero J, Jimenez-Monzon R, Estevez F, Quintana J, Guerra B Int J Biol Sci. 2023; 19(6):1731-1747.

PMID: 37063429 PMC: 10092761. DOI: 10.7150/ijbs.78554.

Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer.

de Paula B, Kieran R, Koh S, Crocamo S, Abdelhay E, Munoz-Espin D Mol Cancer Ther. 2023; 22(5):583-598.

PMID: 36752780 PMC: 10157365. DOI: 10.1158/1535-7163.MCT-22-0643.

MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy.

Hosseinzadeh A, Merikhian P, Naseri N, Eisavand M, Farahmand L Cancer Cell Int. 2022; 22(1):110.

PMID: 35248049 PMC: 8897942. DOI: 10.1186/s12935-022-02523-z.

References

Foight G, Ryan J, Gulla S, Letai A, Keating A . Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol. 2014; 9(9):1962-8. PMC: 4168798. DOI: 10.1021/cb500340w. View

Perciavalle R, Opferman J . Delving deeper: MCL-1's contributions to normal and cancer biology. Trends Cell Biol. 2012; 23(1):22-9. PMC: 3532576. DOI: 10.1016/j.tcb.2012.08.011. View

Hasegawa M, Sinha R, Kumar M, Alam M, Yin L, Raina D . Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation. Clin Cancer Res. 2015; 21(10):2338-47. PMC: 4433879. DOI: 10.1158/1078-0432.CCR-14-3000. View

Ahmad R, Alam M, Rajabi H, Kufe D . The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J Biol Chem. 2012; 287(25):20866-75. PMC: 3375510. DOI: 10.1074/jbc.M112.357293. View

Oakes S, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F . Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci U S A. 2011; 109(8):2766-71. PMC: 3286989. DOI: 10.1073/pnas.1104778108. View

Raina D, Agarwal P, Lee J, Bharti A, McKnight C, Sharma P . Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS One. 2015; 10(8):e0135156. PMC: 4534190. DOI: 10.1371/journal.pone.0135156. View

Abulwerdi F, Liao C, Liu M, Azmi A, Aboukameel A, Mady A . A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2013; 13(3):565-75. PMC: 4174574. DOI: 10.1158/1535-7163.MCT-12-0767. View

Goodwin C, Rossanese O, Olejniczak E, Fesik S . Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death Differ. 2015; 22(12):2098-106. PMC: 4816117. DOI: 10.1038/cdd.2015.73. View

Kufe D . MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2012; 32(9):1073-81. PMC: 3621754. DOI: 10.1038/onc.2012.158. View

10.

Belmar J, Fesik S . Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther. 2014; 145:76-84. PMC: 4340597. DOI: 10.1016/j.pharmthera.2014.08.003. View

11.

Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D . MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res. 2005; 65(22):10413-22. DOI: 10.1158/0008-5472.CAN-05-2474. View

12.

Kozopas K, Yang T, Buchan H, Zhou P, Craig R . MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A. 1993; 90(8):3516-20. PMC: 46331. DOI: 10.1073/pnas.90.8.3516. View

13.

Tse C, Shoemaker A, Adickes J, Anderson M, Chen J, Jin S . ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008; 68(9):3421-8. DOI: 10.1158/0008-5472.CAN-07-5836. View

14.

Kharbanda A, Rajabi H, Jin C, Raina D, Kufe D . Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer. Mol Cancer Res. 2013; 11(7):714-23. PMC: 3720729. DOI: 10.1158/1541-7786.MCR-12-0668. View

15.

Hiraki M, Nishimura J, Takahashi H, Wu X, Takahashi Y, Miyo M . Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer. Mol Ther Nucleic Acids. 2015; 4:e231. PMC: 4354340. DOI: 10.1038/mtna.2015.5. View

16.

Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M . Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 2011; 10(5):806-16. PMC: 3092019. DOI: 10.1158/1535-7163.MCT-10-1050. View

17.

Zheng L, Yang W, Zhang C, Ding W, Zhu H, Lin N . GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett. 2011; 309(1):27-36. DOI: 10.1016/j.canlet.2011.05.011. View

18.

Domina A, Vrana J, Gregory M, Hann S, Craig R . MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004; 23(31):5301-15. DOI: 10.1038/sj.onc.1207692. View

19.

Williams M, Cook R . Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?. Oncotarget. 2015; 6(6):3519-30. PMC: 4414133. DOI: 10.18632/oncotarget.2792. View

20.

Takahashi H, Jin C, Rajabi H, Pitroda S, Alam M, Ahmad R . MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene. 2015; 34(40):5187-97. PMC: 4530107. DOI: 10.1038/onc.2014.442. View